This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the
Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant
Tumors who are refractory or resistant to standard therapy, or without available standard or
curative therapy.